Abstract:Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence is increasing in parallel with an obesity pandemic, calling for novel strategies for prevention and treatment. We defined a circulating proteome of human MASLD across ≈7000 proteins in ≈5000 individuals from diverse, at-risk populations across the metabolic health spectrum, demonstrating reproducible diagnostic performance and specifying both known and novel metabolic pathways relevant to MASLD (central carbon and amino acid metabolism, hepatocyte regeneration, inflammation, fibrosis, insulin sensitivity). A parsimonious proteomic signature of MASLD was associated with a protection from MASLD and its related multi-system metabolic consequences in >26000 free-living individuals, with an additive effect to polygenic risk. The MASLD proteome was encoded by genes that demonstrated transcriptional enrichment in liver, with spatial transcriptional activity in areas of steatosis in human liver biopsy and dynamicity for select targets in human liver across stages of steatosis. We replicated several top relations from proteomics and spatial tissue transcriptomics in a humanized “liver-on-a-chip” model of MASLD, highlighting the power of a full translational approach to discovery in MASLD. Collectively, these results underscore utility of blood-based proteomics as a dynamic “liquid biopsy” of human liver relevant to clinical biomarker and mechanistic applications.

What problem does this paper attempt to address?

This paper attempts to address the diagnosis and prognosis of Metabolic Dysfunction - Associated Steatotic Liver Disease (MASLD). Specifically, the study aims to identify circulating protein markers associated with MASLD through plasma proteomics analysis in a large - scale population, and explore the diagnostic performance of these markers under different metabolic risk states and their predictive value for MASLD - related clinical outcomes. In addition, the study also hopes to verify the expression patterns of these protein markers in the liver and their dynamic changes during the progression of MASLD by integrating single - cell and spatial transcriptome data of liver tissues, thereby providing new insights into the pathogenesis of MASLD. ### Main research objectives: 1. **Identify MASLD - related circulome**: Determine specific proteins associated with MASLD through large - scale proteomics analysis of approximately 5,000 individuals. 2. **Verify the diagnostic performance of the proteome**: Evaluate the diagnostic performance of these protein markers under different metabolic risk states, especially in the detection of early - stage MASLD. 3. **Explore the clinical prognostic value of the proteome**: Investigate the relationship between these protein markers and MASLD - related clinical outcomes (such as chronic non - alcoholic liver disease, diabetes, etc.), and their prognostic value in long - term follow - up. 4. **Verify the tissue origin of the proteome**: Confirm the expression patterns of these protein markers in the liver and their dynamic changes in different MASLD stages through single - cell and spatial transcriptomics techniques. 5. **Construct a "liver - on - a - chip" model**: Use a humanized "liver - on - a - chip" model to verify proteomics and transcriptomics results and further verify the biological significance of these markers in the early stage of MASLD. ### Research methods: - **Proteomics analysis**: Utilize the SomaScan and Olink platforms to perform proteomics analysis on plasma samples from multiple large cohorts (such as CARDIA, UK Biobank, CCHC). - **Statistical modeling**: Identify proteins associated with MASLD through univariate and multivariate regression models and construct a MASLD scoring model. - **Clinical validation**: Verify the diagnostic performance and prognostic value of the MASLD scoring model in an independent cohort. - **Transcriptomics analysis**: Analyze the expression patterns of these protein markers in the liver using single - cell and spatial transcriptomics techniques. - **"Liver - on - a - chip" model**: Construct a humanized "liver - on - a - chip" model to simulate the pathological features of the early stage of MASLD and verify proteomics and transcriptomics results. ### Expected results: - **Diagnostic tool**: Develop a blood - based proteomics marker for the early diagnosis of MASLD. - **Prognostic model**: Establish a multivariate model capable of predicting MASLD - related clinical outcomes to support clinical decision - making. - **Mechanism research**: Reveal the pathogenesis of MASLD and provide a theoretical basis for new drug development and treatment strategies. Through these studies, the paper hopes to provide new tools and methods for the early diagnosis, risk stratification, and treatment of MASLD.

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

Deep Proteome Profiling of Metabolic Dysfunction-Associated Steatotic Liver Disease

Identification of signature gene set as highly accurate determination of MASLD progression

Applying Proteomics in Metabolic Dysfunction-Associated Steatotic Liver Disease: from Mechanism to Biomarkers

Organ damage proteomic signature identifies patients with MASLD at-risk of systemic complications.

Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression

MegaMASLD: An interactive platform for exploring stratified transcriptomic signatures in MASLD progression

Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment

A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD

Multisystem health comorbidity networks of metabolic dysfunction-associated steatotic liver disease

A functional genomic framework to elucidate novel causal metabolic dysfunction-associated fatty liver disease genes

Multiscale integrative analyses unveil immune-related diagnostic signature for the progression of MASLD

Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease

Spatial Omics Reveals that Cancer-Associated Glycan Changes Occur Early in Liver Disease Development in a Western Diet Mouse Model of MASLD

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

Spatial genomics: mapping human steatotic liver disease

Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we?

Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies

Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies

A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis

Novel eicosanoid signature in plasma provides diagnostic for metabolic dysfunction-associated steatotic liver disease